Panellists in this video:
• Ms Viveka Roychowdhury, Editor, Express Pharma (Moderator)
• Dr Praveen Khullar, ED, VerGo Pharma Research Laboratories
• Mr Sreehari Babu P, CEO, HyCON Labs
• Mr Jayanta Kumar Mandal, CEO & MD, APDM Pharmaceutical
Key Highlights:
[1] India’s FR&D opportunity lies beyond cost arbitrage and AI adoption.
[2] Moving from scientist to entrepreneur is challenging, but the opportunity to create impact has never been greater.
[3] Breakthrough outcomes emerge when strong ideas are matched with the right talent, robust validation processes, and cross-functional collaboration.
[4] Future growth will come from addressing unmet patient needs, pursuing deeper scientific inquiry, and developing solutions that create meaningful clinical impact.
[5] Successful FR&D businesses need more than science. Lateral thinking, strong IP strategy, and ease of doing business are critical enablers.